In addition, LD in the syngeneic orthotopic oral cancer model not only suppressed tumor growth, decreased tumor aggressiveness but also created an immune-active microenvironment by downregulation of TGFβ signaling and enhanced CD8+ T-cell activity, leading to the improved anti-PD-1 treatment. The gene discussed is PDCD1; the disease is lip and oral cavity carcinoma.